Artivion, Inc. (NYSE:AORT) VP Sells $238,420.20 in Stock

Artivion, Inc. (NYSE:AORT) VP Matthew A. Getz sold 9,420 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the sale, the vice president now owns 34,116 shares in the company, valued at $863,475.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Artivion Stock Up 0.7 %

AORT stock traded up $0.17 during midday trading on Monday, hitting $25.21. The company’s stock had a trading volume of 157,076 shares, compared to its average volume of 227,155. The company has a debt-to-equity ratio of 1.07, a current ratio of 6.04 and a quick ratio of 4.26. Artivion, Inc. has a twelve month low of $12.16 and a twelve month high of $29.24. The company’s fifty day moving average price is $25.51 and its 200 day moving average price is $22.44. The stock has a market capitalization of $1.05 billion, a P/E ratio of -104.33 and a beta of 1.75.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AORT. Lake Street Capital increased their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Needham & Company LLC restated a “buy” rating and set a $30.00 price objective on shares of Artivion in a report on Friday, August 9th. Stifel Nicolaus raised their price objective on shares of Artivion from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Oppenheimer raised their price objective on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Friday, August 9th.

Institutional Investors Weigh In On Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC lifted its stake in Artivion by 4.7% in the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after purchasing an additional 124,725 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Artivion by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after purchasing an additional 33,982 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Artivion by 5.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,686,502 shares of the company’s stock worth $30,156,000 after purchasing an additional 80,214 shares during the period. Wasatch Advisors LP increased its holdings in shares of Artivion by 108.8% in the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock valued at $22,928,000 after purchasing an additional 564,549 shares during the last quarter. Finally, First Eagle Investment Management LLC raised its position in shares of Artivion by 4.9% in the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after purchasing an additional 27,906 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.